OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
SNTP58

Synektik SA

Advanced Medical Equipment & TechnologyVerified

Synektik maintains a strong liquidity position with a current ratio of 1.65 and cash and equivalents of 84.25 million PLN, which supports operational flexibility and short-term obligations. The company's debt-to-equity ratio of 0.18 indicates a conservative capital structure, with long-term debt at 40.23 million PLN and total equity at 222.78 million PLN. Free cash flow of 57.36 million PLN and operating cash flow of 77.73 million PLN further reinforce its liquidity profile. The company's profitability is robust, with a return on equity of 45.87% and return on assets of 21%, both exceeding typical thresholds for the healthcare equipment industry. Operating income of 157.02 million PLN and net income of 102.19 million PLN reflect strong cost control and revenue generation. Gross profit of 242.59 million PLN on revenue of 681.29 million PLN suggests a healthy margin structure. Synektik's revenue is concentrated in a single business segment, with no disclosed geographic diversification in the latest financials. This lack of diversification may expose the company to regional market risks, particularly in the healthcare equipment sector. The company's growth trajectory is supported by strong analyst sentiment, with a mean price target of 319.38 PLN and a median of 312.65 PLN. Analysts have issued three strong-buy and two buy recommendations, with no hold or negative ratings. The absence of negative analyst sentiment suggests confidence in the company's near-term performance. Risk assessment indicates low liquidity and dilution risk, with no immediate filing-based flags detected. The company's capital structure remains stable, with no dilution potential identified in the latest financial data. However, the healthcare equipment industry is subject to regulatory and technological changes, which could impact long-term performance. Recent events include strong analyst coverage and positive price target estimates, with no disclosed earnings call transcripts or regulatory filings indicating material changes in the company's operations. The absence of recent negative events supports the current positive outlook.

30-day price · SNTP-17.60 (-5.8%)
Low$275.00High$309.80Close$286.40As of25 May, 00:00 UTC
Profile
CompanySynektik SA
TickerSNTP.WA
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryAdvanced Medical Equipment & Technology
AI analysis

Business. Synektik SA develops and distributes advanced medical equipment and technology solutions, primarily serving healthcare institutions and providers.

Classification. Synektik is classified in the Healthcare sector under Advanced Medical Equipment & Technology with a confidence level of 0.92.

Synektik maintains a strong liquidity position with a current ratio of 1.65 and cash and equivalents of 84.25 million PLN, which supports operational flexibility and short-term obligations. The company's debt-to-equity ratio of 0.18 indicates a conservative capital structure, with long-term debt at 40.23 million PLN and total equity at 222.78 million PLN. Free cash flow of 57.36 million PLN and operating cash flow of 77.73 million PLN further reinforce its liquidity profile. The company's profitability is robust, with a return on equity of 45.87% and return on assets of 21%, both exceeding typical thresholds for the healthcare equipment industry. Operating income of 157.02 million PLN and net income of 102.19 million PLN reflect strong cost control and revenue generation. Gross profit of 242.59 million PLN on revenue of 681.29 million PLN suggests a healthy margin structure. Synektik's revenue is concentrated in a single business segment, with no disclosed geographic diversification in the latest financials. This lack of diversification may expose the company to regional market risks, particularly in the healthcare equipment sector. The company's growth trajectory is supported by strong analyst sentiment, with a mean price target of 319.38 PLN and a median of 312.65 PLN. Analysts have issued three strong-buy and two buy recommendations, with no hold or negative ratings. The absence of negative analyst sentiment suggests confidence in the company's near-term performance. Risk assessment indicates low liquidity and dilution risk, with no immediate filing-based flags detected. The company's capital structure remains stable, with no dilution potential identified in the latest financial data. However, the healthcare equipment industry is subject to regulatory and technological changes, which could impact long-term performance. Recent events include strong analyst coverage and positive price target estimates, with no disclosed earnings call transcripts or regulatory filings indicating material changes in the company's operations. The absence of recent negative events supports the current positive outlook.
Key takeaways
  • Synektik maintains a strong liquidity position with a current ratio of 1.65 and 84.25 million PLN in cash and equivalents.
  • The company's profitability is robust, with a return on equity of 45.87% and return on assets of 21%.
  • Analysts have issued three strong-buy and two buy recommendations, with no hold or negative ratings.
  • The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification.
  • Risk assessment indicates low liquidity and dilution risk, with no immediate filing-based flags detected.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyPLN
Revenue$681.3M
Gross profit$242.6M
Operating income$157.0M
Net income$102.2M
R&D
SG&A
D&A
SBC
Operating cash flow$77.7M
CapEx-$18.1M
Free cash flow$57.4M
Total assets$486.6M
Total liabilities$263.8M
Total equity$222.8M
Cash & equivalents$84.3M
Long-term debt$40.2M
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$222.8M
Net cash$44.0M
Current ratio1.6
Debt/Equity0.2
ROA21.0%
ROE45.9%
Cash conversion76.0%
CapEx/Revenue-2.7%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskLow
  • No immediate filing-based liquidity or dilution flags were detected.
Industry benchmarks
Activity: Advanced Medical Equipment & Technology · cohort 109 companies
MetricSNTPActivity
Op margin23.0%-19.9% medp25 -150.5% · p75 8.7%top quartile
Net margin15.0%-18.4% medp25 -146.8% · p75 8.0%top quartile
Gross margin35.6%49.9% medp25 36.2% · p75 66.3%bottom quartile
R&D / revenue6.2% medp25 4.7% · p75 12.0%
CapEx / revenue-2.7%-3.5% medp25 -7.8% · p75 -1.4%above median
Debt / equity18.0%14.5% medp25 0.9% · p75 54.2%above median
Observations
IR observations
Mean price target319.38 PLN
Median price target312.65 PLN
High price target357.00 PLN
Low price target295.20 PLN
Mean recommendation1.40 (1=strong buy, 5=strong sell)
Strong-buy count3.00
Buy count2.00
Hold count0.00
Sell count0.00
Strong-sell count0.00
Mean EPS estimate17.91 PLN
Last actual EPS11.98 PLN
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod financials
no public URL
2026-05-24 17:49 UTC#5a60fbe4
Source: analysis-pipeline (hybrid)Generated: 2026-05-29 12:24 UTCJob: eff10658